Normally things tend to slow down a bit between Thanksgiving and New Year's Day. But this week alone we've already seen two biopharma partnership deals in as many days. First Pfizer and Protalix and now AstraZeneca and Targacept.
In today's trading session, a total of 55 stocks in the S&P 500 reached new 52-week highs. Here is a look at those companies.
Following are the day’s biggest winners and losers. Find out why shares of Pfizer and Guess? popped while Human Genome and DynCorp dropped.
Stocks kicked off December with a rally Tuesday as Dubai fears subsided and the dollar retreated, pushing gold to a new record above $1,200 an ounce. The Dow gained 1.2 percent to close at its highest level since Oct. 2008.
Pfizer today announced it's paying what amounts to chump change (a total of $115 million over time) for the rights to a biotech drug to treat a rare disease. And as I write this, investors are rewarding the world's biggest drug company by making its stock the biggest percentage gainer among the Dow 30.
Stocks kicked off December with a rally Tuesday as Dubai fears subsided and the dollar retreated, pushing gold to a new record above $1,200 an ounce.
Genzyme, the biotechnology company already reeling from problems manufacturing its drugs for rare diseases, will soon have a formidable new competitor — the pharmaceutical giant Pfizer.
With the health care debate continuing, how can investors make money in the sector? Barbara Ryan, managing director and senior pharmaceuticals analyst at Deutsche Bank Securities, and Charles Boorady, health care providers analyst at Citigroup, shared their insights.
In today's trading session, a total of 50 stocks in the S&P 500 reached new 52-week highs. Here is a look at those companies.
The latest erectile dysfunction drug is showing promise of working even faster than those already on the market. Considering it's $3.5 billion market, what's the trade?
The Baltic Dry Shipping Index, a leading economic indicator used by market insiders to gauge global demand for dry commodities, hit another year-high on Wednesday. Urs Dur, vice president and logistics analyst at Lazard Capital Markets, discussed the index's significance and what investors should expect going forward.
Trading desks idle as light volume continues. It started on November 1st — sell-side desks started seeing a drop in trading volume, and it has continued through the month. What gives?
VVUS this morning unveiled positive late-stage test results on the ED pill. The company touts that it takes effect in less than 30 minutes and it's out of your system within six hours or so.
Stocks opened lower on Tuesday, after a sharp rally in the prior session. Where should investors be looking and how should they play the markets? David Spika, VP and investment strategist at WHG Funds and Bill Smead, CEO and CIO of Smead Capital Management shared their outlooks.
John Paulson’s hedge fund group, the Paulson Funds, had another strong, if not spectacular quarter, according to an investment letter obtained by CNBC.
Pfizer said it would pull 1,400 jobs out of New London within two years and move most of them a few miles away to a campus it owns in Groton, Conn., as a cost-cutting measure. It would leave behind the city’s biggest office complex and an adjacent swath of barren land that was cleared of dozens of homes to make room for a hotel, stores and condominiums that were never built.
No doubt the widespread use of solar and wind power is ideal, but it’ll be a long time before the mass adoption of those alternative energies is a reality. In the meantime, Cramer says, the US should shift its focus to natural gas.
The latest overall job loss numbers showed a loss of 190,000 jobs in September and the unemployment rate rose to 10.2%, the highest unemployment rate since April 1983. The August and September numbers were revised as well. Here is a breakdown of where the job losses were as well as which sectors were adding jobs.
I am not a Trekkie. In fact, sci-fi and fantasy are two of of my least favorite genres. But the Vulcan salutation was one of the first things I thought of when I went to the facelifted Merck Web site this morning to link to and print the press release about the new Merck.
Don’t make your move until then, he says.